Eli Lilly & Co. is tapping the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – ...

JonesResearch initiated coverage of OnKure Therapeutics (OKUR) with a Buy rating and $32 price target. The clinical stage precision oncology ...

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target of ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where Relay Therapeutics Inc (NASDAQ:RLAY) stands against the other ...

For instance, in the second-largest M&A deal announced so far this year, Eli Lilly has acquired Scorpion Therapeutics for $2.5bn. The deal is focused on Scorpion’s pipeline of precision cancer drugs, ...

Glick, Ph.D., who has been with the firm since its inception in 2021 and was previously founder of IFM Therapeutics and Scorpion Therapeutics ... Foresite Capital, Logos Opportunities Fund ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

Plymouth drugmaker IDRx was bought by GSK plc (NYSE: GSK) for $1 billion upfront, while Eli Lilly and Co. paid Boston-based Scorpion Therapeutics Inc. up to $2.5 billion for its lead cancer drug.